Novavax Announces Positive Top-Line Data from Dose-Confirmatory Phase 2 Clinical Trial of its RSV Vaccine Candidate in Women of Childbearing Age

Vaccine candidate was well-tolerated with no vaccine-related serious adverse events Highest immune responses observed with a single dose of vaccine combined with aluminum phosphate adjuvant Women with the lowest baseline levels of RSV neutralizing antibodies had the largest increases following immunization, consistent with prior data Palivizumab-like antibodies exceeded levels observed in previous trials  High levels of antibodies developed within 14 days after …

Download Presentation by Michel Zaffran, OPTIMIZE

In November 2012 over 200 delegates participated in the 13th Annual World Vaccine Congress Lyon in France. This event brings together vaccine leaders and policy makers from around the globe. Attendees at this highly successful event were fortunate enough to hear this exciting presentation delivered by Michel Zaffran, OPTIMIZE, ‘Improve immunization programmes effectiveness, efficiency and safety : Innovative systems and …

Challenges and Impact of Conducting Vaccine Trials in Africa and Asia

  Sonali Kochhar, M.D. Clinical Research and Drug Developmental Specialist, PATH joined us at the World Vaccine Congress Lyon 2012  to discuss the challenges and impact of conducting of vaccine trials in Africa and Asia. Clinical Research in Developing Countries is limited due to the climate under which the vaccine industry has to work in Developing Countries- a climate characterised …